These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

689 related items for PubMed ID: 25382325

  • 1. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
    Feng X, Gu F, Chen W, Liu Y, Wei H, Liu L, Yin S, Da Z, Sun L.
    Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
    [Abstract] [Full Text] [Related]

  • 2. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M, Goyal A, Jaryal A, Sharma A, Gupta PK, Ramachandran R, Kumar V, Kohli HS, Sakhuja V, Jha V, Gupta KL.
    Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
    [Abstract] [Full Text] [Related]

  • 3. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
    Sedhain A, Hada R, Agrawal RK, Bhattarai GR, Baral A.
    BMC Nephrol; 2018 Jul 11; 19(1):175. PubMed ID: 29996800
    [Abstract] [Full Text] [Related]

  • 4. Mizoribine for the treatment of lupus nephritis in children and adolescents.
    Tanaka H, Tsugawa K, Tsuruga K, Suzuki K, Nakahata T, Ito E, Waga S.
    Clin Nephrol; 2004 Dec 11; 62(6):412-7. PubMed ID: 15630899
    [Abstract] [Full Text] [Related]

  • 5. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
    Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, Meroni P, Messa P, Sinico AR.
    Rheumatology (Oxford); 2014 Sep 11; 53(9):1570-7. PubMed ID: 24505125
    [Abstract] [Full Text] [Related]

  • 6. A Comparison Of Mycophenolate Mofetil And Cyclophosphamide As Lupus Nephritis Induction Therapy.
    Gul H, Mushtaq MS, Salim B, Samreen S, Nasim A, Khan M.
    J Ayub Med Coll Abbottabad; 2020 Sep 11; 32(4):454-458. PubMed ID: 33225643
    [Abstract] [Full Text] [Related]

  • 7. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis.
    Koo HS, Kim YC, Lee SW, Kim DK, Oh KH, Joo KW, Kim YS, Ahn C, Han JS, Kim S, Chin HJ.
    Lupus; 2011 Nov 11; 20(13):1442-9. PubMed ID: 21951944
    [Abstract] [Full Text] [Related]

  • 8. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
    Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, Pan X, Yu H.
    Nephrol Dial Transplant; 2007 Jul 11; 22(7):1933-42. PubMed ID: 17405792
    [Abstract] [Full Text] [Related]

  • 9. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.
    Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, Li L.
    Chin Med J (Engl); 2002 May 11; 115(5):705-9. PubMed ID: 12133539
    [Abstract] [Full Text] [Related]

  • 10. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis.
    Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, Shen P, Chen N.
    Nephrol Dial Transplant; 2012 Apr 11; 27(4):1467-72. PubMed ID: 21917733
    [Abstract] [Full Text] [Related]

  • 11. Induction therapy for pediatric onset class IV lupus nephritis: Mycophenolate Mofetil versus Cyclophosphamide.
    Chbihi M, Eveillard LA, Riller Q, Brousse R, Berthaud R, Quartier P, Salomon R, Charbit M, Avramescu M, Biebuyck N, Dehoux L, Garcelon N, Duong-Van-Huyen JP, Bader-Meunier B, Boyer O.
    J Nephrol; 2023 Apr 11; 36(3):829-839. PubMed ID: 36208405
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: A systematic review and meta-analysis.
    Jiang YP, Zhao XX, Chen RR, Xu ZH, Wen CP, Yu J.
    Medicine (Baltimore); 2020 Sep 18; 99(38):e22328. PubMed ID: 32957400
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis.
    Basu B, Roy B, Babu BG.
    Pediatr Nephrol; 2017 Jun 18; 32(6):1013-1021. PubMed ID: 28191596
    [Abstract] [Full Text] [Related]

  • 14. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
    Joo YB, Kang YM, Kim HA, Suh CH, Kim TJ, Park YW, Lee J, Lee JH, Yoo DH, Bae SC, Lee HS, Bang SY.
    Int J Rheum Dis; 2018 May 18; 21(5):1031-1039. PubMed ID: 29611341
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
    Prasad N, Kurian J, Agarwal V, Bhadauria D, Behera M, Yacha M, Kushwaha R, Agrawal V, Jain M, Gupta A.
    Lupus; 2020 Jul 18; 29(8):845-853. PubMed ID: 32437258
    [Abstract] [Full Text] [Related]

  • 16. Current therapies for lupus nephritis in an ethnically heterogeneous cohort.
    Rivera TL, Belmont HM, Malani S, Latorre M, Benton L, Weisstuch J, Barisoni L, Tseng CE, Izmirly PM, Buyon JP, Askanase AD.
    J Rheumatol; 2009 Feb 18; 36(2):298-305. PubMed ID: 19040310
    [Abstract] [Full Text] [Related]

  • 17. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH, Song GG.
    Lupus; 2015 Dec 18; 24(14):1520-8. PubMed ID: 26162684
    [Abstract] [Full Text] [Related]

  • 18. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis.
    Smith E, Al-Abadi E, Armon K, Bailey K, Ciurtin C, Davidson J, Gardner-Medwin J, Haslam K, Hawley D, Leahy A, Leone V, McErlane F, Mewar D, Modgil G, Moots R, Pilkington C, Ramanan A, Rangaraj S, Riley P, Sridhar A, Wilkinson N, Beresford MW, Hedrich CM.
    Lupus; 2019 Apr 18; 28(5):613-620. PubMed ID: 30871425
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.
    Kawazoe M, Kaneko K, Yamada Z, Masuoka S, Mizutani S, Yamada S, Shikano K, Sato H, Kaburaki M, Muraoka S, Kawai S, Nanki T.
    Clin Rheumatol; 2019 Jun 18; 38(6):1571-1578. PubMed ID: 30778862
    [Abstract] [Full Text] [Related]

  • 20. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
    Jesus D, Rodrigues M, da Silva JAP, Inês L.
    Lupus; 2018 Jul 18; 27(8):1358-1362. PubMed ID: 29448882
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.